JAMA/tukuz.com
Feb 7, 2026, 06:50
ACOG 2023 Guideline on Premenstrual Disorders – JAMA
JAMA shared a post on LinkedIn:
“JAMA Clinical Guidelines Synopsis: The 2023 American College of Obstetricians and Gynecologists guideline on the management of premenstrual disorders recommends selective serotonin reuptake inhibitors (SSRIs)—used intermittently or continuously—as effective for affective symptoms, with evidence supporting their use.
Combined oral contraceptive pills, particularly those containing drospirenone, and cognitive behavior therapy are also recommended.
Treatment selection should consider individual patient goals, presence of affective or physical symptoms, and need for contraception.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Mar 12, 2026, 14:29Fahima Hussain: When Reproductive Trauma Goes Unspoken
-
Mar 12, 2026, 12:56Vinnie Arvin Amir: New AI Study Explores Immune Factors in Pregnancy Loss
-
Mar 12, 2026, 12:53Deep Learning Bridges the Diagnostic Gap in Chronic Endometritis – Medicina MDPI
-
Mar 12, 2026, 12:49Explore the ASRM CELL Training Lab – ASRM
-
Mar 12, 2026, 02:28Anthony Griffiths to Discuss Multidisciplinary Approaches to Endometriosis Care – BSGI
-
Mar 11, 2026, 12:36Christopher Robinson: B-Lynch Uterine Compression Technique Discussed in AJOG Expert Review
-
Mar 11, 2026, 09:55Abstract Deadline and Early Registration Approaching for ESHRE Embryology 2026 – ESHRE
-
Mar 11, 2026, 08:57How Hyaluronic Acid Medium Improves Live Birth Rate? – RBMO
-
Mar 11, 2026, 08:46PCOS and Higher BMI Linked to Increased Risk of Type 2 Diabetes – Fertility and Sterility